CardieX Limited announced new senior executive changes and appointments to support its repositioning as global health technology provider and ongoing restructuring to focus on new growth opportunities Board restructure and new appointments a key step forward as CardieX positions for long-term growth and expansion into new markets. Doug Kurschinski promoted to Executive VP & Head of Global Sales of CardieX's AtCor Medical division. Former Masimo Inc. executive ZiHan Li appointed Director of Corporate Development of CardieX. Subsequently promoted to VP of Corporate Development in January 2019. Lin is focused on expanding the opportunity for CardieX's products in the Chinese market as well as accelerating the commercialisation of CardieX's cardiovascular technologies into new devices and technologies. Former Johnson & Johnson Executive joins CardieX as a member of the Company's Advisory Board. Welch to work closely with the CEO and executive team in the development of new opportunities and business strategy with respect to the expansion of CardieX's technologies and reimbursement programs. The appointment of Jarrod White as CFO/Company Secretary. White is a Partner/Director at Traverse Accountants in Sydney and has significant experience in listed company compliance, finance and accounts management. Long serving Managing Director, Duncan Ross transitioned out of his executive role during the year following the global sales force restructure. Ross was formerly CEO and Managing Director and then appointed to the newly created role of "EVP & Head of Global Sales" on 1 December 2017. Ross' employment was terminated at the end of June 2018.

The company also announced that Asia-Pacific sales of SphygmoCor technology relocated to AtCor's head office in Chicago, USA. Sydney sales operations shuttered. All sales and training undertaken by USA staff utilizing virtual and online training platforms. Seemless transition with no impact on global sales operations.